Bictegravir/lenacapavir
| Combination of | |
|---|---|
| Bictegravir | Integrase inhibitor |
| Lenacapavir | Capsid inhibitor |
| Clinical data | |
| Trade names | Bixlenvo |
| Legal status | |
| Legal status |
|
Bictegravir/lenacapavir, sold under the brand name Bixlenvo, is a combination drug used for the treatment of HIV-1.
It is being developed by Gilead Sciences and has completed Phase III trials in late 2025.[1][2][3] The drug is a combination of two other anti-HIV medications from Gilead, bictegravir and lenacapavir.
References
- ↑ Sagonowsky E (13 November 2025). "Gilead hails phase 3 victory for single-tablet combo of bictegravir and lenacapavir, preps filings". FierceBiotech. Retrieved 15 December 2025.
- ↑ Roy V (15 December 2025). "Gilead's experimental HIV treatment non-inferior to blockbuster drug in trial". Reuters. Retrieved 15 December 2025.
- ↑ Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, et al. (April 2025). "Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)". Clinical Infectious Diseases. 80 (4): 881–888. doi:10.1093/cid/ciae522. PMC 12043062. PMID 39589133.